Nav: Home

Sanford Health studying impact of precision medicine cancer treatments

October 10, 2016

SIOUX FALLS, S.D. - A new study open and enrolling patients at Sanford Health is exploring how genomic profiling might help improve treatment options for patients with advanced or rare forms of cancer. The COMPASS study examines the latest genetic sequencing tools to personalize cancer treatments based on each patient's genomic information.

Steven Powell, M.D., and Sam Milanovich, M.D., both oncologists and cancer researchers, are leading the COMPASS trial. Milanovich brings pediatric expertise to the study.

"A cancer's genetic code holds information that is vital to understanding how cancer affects each person differently," said Powell. "By better understanding cancer genomics, we can identify treatment options that may have not previously been available. COMPASS seeks to help us understand how this testing can be most effectively used for our patients."

COMPASS, which stands for Community Oncology use of Molecular Profiling to personalize the Approach to Specialized cancer treatment at Sanford, analyzes treatment patterns of patients who have profiling completed on tumor tissue or blood samples using validated next-generation sequencing technology from certified commercial laboratories as part of their cancer management. The resulting data is reviewed by the Sanford Genomic Tumor Board to help guide the decision process for the treating cancer team, patient and family. This committee is a panel of experts from across the Sanford footprint in cancer and genetics.

"Many rare and aggressive childhood cancers have limited treatment options," said Milanovich. "COMPASS may help us better understand how cutting-edge genomic testing can be used to open new treatment options and improve therapy for children with cancer."

COMPASS is a follow-up study to GEMMA, which enrolled 120 patients and demonstrated molecular profiling increases awareness of clinical trial and off label treatment options for patients with incurable cancer across Sanford. As part of these trials, the Sanford team has brought in more than 60 different personalized therapy options for patients through clinical trials in the past two years.

To be eligible for COMPASS, participants must have an advanced stage of cancer or have cancer that has no established course of treatment. The study is open to both adult and pediatric patients older than four weeks of age.
-end-
COMPASS has enrollment sites across Sanford. For more information or to enroll, call 877-652-1838.

About Sanford Health

Sanford Health is an integrated health system headquartered in the Dakotas. It is one of the largest health systems in the nation with 43 hospitals and nearly 250 clinics in nine states and four countries. Sanford Health's 27,000 employees, including 1,400 physicians, make it the largest employer in the Dakotas. Nearly $1 billion in gifts from philanthropist Denny Sanford have allowed for several initiatives, including global children's clinics, genomic medicine and specialized centers researching cures for type 1 diabetes, breast cancer and other diseases. For more information, visit sanfordhealth.org.

Sanford Health/Sanford Research

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...